Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 6NIH 3NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Burkitt Lymphoma 4Leukemia, Biphenotypic, Acute 3Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Plasmablastic Lymphoma 1Neuroblastoma 1Lymphoma 1Hodgkin Disease 1

Interventions

Vincristine 6Doxorubicin 5Cyclophosphamide 5merphos 4Specimen Handling 4Radiotherapy 4Prednisone 4Methotrexate 4pegaspargase 3calaspargase pegol 3Prednisolone 3Methylprednisolone 3Hydrocortisone 3Etoposide 3Daunorubicin 3Cytarabine 3Biopsy 3Asparaginase 3exifone 2dexamethasone acetate 2dexamethasone 21-phosphate 2daratumumab 2auricularum 2Thioguanine 2Spinal Puncture 2Mercaptopurine 2Medrol Veriderm 2Magnetic Resonance Spectroscopy 2Filgrastim 2Dexamethasone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × prednylidene × Clear all
NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Children's Oncology Group

Phase 2/3 Not yet recruiting
1,708 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡